J
John G.F. Cleland
Researcher at National Institutes of Health
Publications - 1276
Citations - 125527
John G.F. Cleland is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Heart failure & Ejection fraction. The author has an hindex of 137, co-authored 1172 publications receiving 110227 citations. Previous affiliations of John G.F. Cleland include Northwestern University & Imperial College London.
Papers
More filters
Journal ArticleDOI
2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy : The Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA)
Michele Brignole,Angelo Auricchio,Gonzalo Barón-Esquivias,Pierre Bordachar,Giuseppe Boriani,Ole A. Breithardt,John G.F. Cleland,Jean Claude Deharo,Victoria Delgado,Perry M. Elliott,Bulent Gorenek,Carsten W. Israel,Christophe Leclercq,Cecilia Linde,Lluís Mont,Luigi Padeletti,Richard Sutton,Panos Vardas,José Luis Zamorano,Stephan Achenbach,Helmut Baumgartner,Jeroen J. Bax,Héctor Bueno,Veronica Dean,Christi Deaton,Çetin Erol,Robert Fagard,Roberto Ferrari,David Hasdai,Arno W. Hoes,Paulus Kirchhof,Juhani Knuuti,Philippe Kolh,Patrizio Lancellotti,Aleš Linhart,Petros Nihoyannopoulos,Massimo F Piepoli,Piotr Ponikowski,Per Anton Sirnes,Juan Tamargo,Michal Tendera,Adam Torbicki,William Wijns,Stephan Windecker,Carina Blomström-Lundqvist,Luigi P. Badano,Farid Aliyev,Dietmar Bänsch,Walid Bsata,Peter Buser,Philippe Charron,Jean Claude Daubert,Dan Dobreanu,Svein Faerestrand,Jean-Yves Le Heuzey,Hercules Mavrakis,Theresa McDonagh,José L. Merino,Mostapha M. Nawar,Jens Cosedis Nielsen,Burkert Pieske,Lidija Poposka,Frank Ruschitzka,Isabelle C. Van Gelder,Carol M. Wilson +64 more
TL;DR: 2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy : The Task Force on cardiac paced and resynchronized therapy of the European Society of Cardiology developed in collaboration with the European Heart Rhythm Association.
Journal ArticleDOI
Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial
Philip A. Poole-Wilson,Karl Swedberg,John G.F. Cleland,Andrea Di Lenarda,Peter Hanrath,Michel Komajda,Jacobus Lubsen,Beatrix Lutiger,Marco Metra,Willem J. Remme,Christian Torp-Pedersen,Armin Scherhag,Allan M. Skene +12 more
TL;DR: The results suggest that carvedilol extends survival compared with metoprolol.
Journal ArticleDOI
The EuroHeart Failure survey programme-- a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis.
John G.F. Cleland,Karl Swedberg,Ferenc Follath,Michel Komajda,Alain Cohen-Solal,J.C. Aguilar,Rainer Dietz,Antonello Gavazzi,R. Hobbs,Jerzy Korewicki,Hugo Madeira,V. S. Moiseyev,István Préda,W. H. Van Gilst,J Widimsky,Nick Freemantle,Joanne Eastaugh,James Mason +17 more
TL;DR: Most men but a minority of women who underwent investigation of cardiac function had evidence of moderate or severe left ventricular dysfunction, the main target of current advances in the treatment of heart failure.
Journal ArticleDOI
Rosuvastatin in Older Patients with Systolic Heart Failure
John Kjekshus,Eduard Apetrei,Vivencio Barrios,Michael Böhm,John G.F. Cleland,Jan H. Cornel,Peter H.J.M. Dunselman,Cândida Fonseca,Assen Goudev,Peer Grande,Lars Gullestad,Åke Hjalmarson,Jaromír Hradec,András Jánosi,Gabriel Kamenský,Michel Komajda,Jerzy Korewicki,Timo Kuusi,François Mach,Vyacheslav Mareev,John J.V. McMurray,Naresh Ranjith,Maria Schaufelberger,Johan Vanhaecke,Dirk J. van Veldhuisen,Finn Waagstein,Hans Wedel,John Wikstrand,John Wikstrand +28 more
TL;DR: Rosuvastatin did not reduce the primary outcome or the number of deaths from any cause in older patients with systolic heart failure, although the drug did reduce the numberOf cardiovascular hospitalizations and the drugdid not cause safety problems.
Journal ArticleDOI
Angiotensin-Neprilysin inhibition in heart failure with preserved ejection fraction
Scott D. Solomon,John J.V. McMurray,Inder S. Anand,Junbo Ge,Carolyn S.P. Lam,Aldo P. Maggioni,Felipe Martinez,Milton Packer,Marc A. Pfeffer,Burkert Pieske,Margaret M. Redfield,Jean L. Rouleau,Dirk J. van Veldhuisen,Faiez Zannad,Michael R. Zile,Akshay S. Desai,Brian Claggett,Pardeep S. Jhund,Sergey Boytsov,Josep Comín-Colet,John G.F. Cleland,Hans-Dirk Düngen,Hans-Dirk Düngen,Eva Goncalvesova,Tzvetana Katova,José Francisco Kerr Saraiva,Małgorzata Lelonek,Béla Merkely,Michele Senni,Sanjiv J. Shah,Jingmin Zhou,Adel R. Rizkala,Jianjian Gong,Victor Shi,Martin Lefkowitz +34 more
TL;DR: Sacubitril-valsartan did not result in a significantly lower rate of total hospitalizations for heart failure and death from cardiovascular causes among patients with heart failureand an ejection fraction of 45% or higher, and among 12 prespecified subgroups, there was suggestion of heterogeneity with possible benefit in patients with lower ejection fractions and in women.